Timothy Sangiovanni Sells 1,750 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy Sangiovanni sold 1,750 shares of Zevra Therapeutics stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.82, for a total transaction of $15,435.00. Following the completion of the sale, the senior vice president directly owned 20,924 shares of the company’s stock, valued at approximately $184,549.68. The trade was a 7.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Zevra Therapeutics Trading Down 2.1%

Zevra Therapeutics stock opened at $9.16 on Wednesday. Zevra Therapeutics, Inc. has a one year low of $6.19 and a one year high of $13.16. The company’s fifty day moving average price is $8.67 and its two-hundred day moving average price is $9.41. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. The company has a market capitalization of $515.71 million, a price-to-earnings ratio of 19.49 and a beta of 0.99.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The company had revenue of $26.06 million during the quarter, compared to the consensus estimate of $26.64 million. On average, analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ZVRA shares. Cantor Fitzgerald reduced their price objective on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research report on Tuesday, December 30th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $22.80.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Zevra was invited to ring the Nasdaq opening bell on Feb. 9, an elective PR/visibility event for CEO Neil McFarlane to deliver remarks that may attract investor attention and boost short-term volume and awareness. Article Title
• Neutral Sentiment: A recent MarketBeat/InsiderTrades summary consolidates the SEC filings and provides context on Zevra’s valuation, analyst ratings (consensus “Moderate Buy” and $22.80 average target) and that the company is commercial-stage with ongoing clinical programs — useful background but not an immediate catalyst. Article Title
• Negative Sentiment: CEO Neil F. McFarlane sold 91,000 shares on Feb. 2 at an average price of $9.38 (~$853,580), reducing his ownership by ~19.98%. Large CEO sales often weigh on sentiment because they can be perceived as material insider profit-taking. Article Title
• Negative Sentiment: Adrian W. Quartel sold 4,533 shares on Jan. 30 at ~$8.83 per share (~$40,026), cutting his stake by ~31.8%. Article Title
• Negative Sentiment: Joshua Schafer sold 3,375 shares on Jan. 30 at ~$8.83 per share (~$29,801), an ~8.27% reduction in his position. Article Title
• Negative Sentiment: SVP Timothy Sangiovanni sold 1,750 shares on Jan. 30 at ~$8.82 per share (~$15,435), a ~7.72% reduction in his holding; the sale was reported in multiple filings. Article Title InsiderTrades

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in Zevra Therapeutics during the third quarter worth about $8,676,000. Rubric Capital Management LP raised its holdings in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after acquiring an additional 740,584 shares in the last quarter. Royce & Associates LP bought a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $6,574,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after acquiring an additional 550,000 shares during the period. Finally, Nantahala Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 34.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after purchasing an additional 500,000 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.